APYX
Price
$3.00Alerts
Change
+$0.07 (+2.39%)
Updated
Nov 11 closing price
Capitalization
123.42M
126 days until earnings call
Intraday BUY SELL Signals
EMBC
Price
$6.53Alerts
Change
+$0.10 (+1.56%)
Updated
Nov 11 closing price
Capitalization
350.72M
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

APYX vs EMBC

APYX vs EMBC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
APYX vs. EMBC commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APYX is a Hold and EMBC is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for APYX with price predictions
Nov 11, 2026

APYX's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for APYX turned positive on October 12, 2026. Looking at past instances where APYX's MACD turned positive, the stock continued to rise in 41 of 45 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on APYX as a result. In 90 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

APYX moved above its 50-day moving average on November 05, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for APYX crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Following a +7.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where APYX advanced for three days, in 196 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for APYX moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 22 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 57 of 59 cases where APYX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where APYX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

APYX broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for APYX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.575) is normal, around the industry mean (4.142). P/E Ratio (-14.650) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.390) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.196) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. APYX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for EMBC with price predictions
Nov 11, 2026

EMBC's RSI Oscillator recovers from overbought zone

The 10-day RSI Oscillator for EMBC moved out of overbought territory on October 27, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 instances where the indicator moved out of the overbought zone. In 21 of the 25 cases the stock moved lower in the days that followed. This puts the odds of a move down at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for EMBC turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMBC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

EMBC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 63 cases where EMBC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on EMBC as a result. In 61 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

Following a +1.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMBC advanced for three days, in 191 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 110 of 151 cases where EMBC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.572) is normal, around the industry mean (4.964). P/E Ratio (4.127) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.006) settles around the average of (0.005) among similar stocks. P/S Ratio (0.300) is also within normal values, averaging (56.876).

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. EMBC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EMBC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
APYX: Fundamental Ratings
APYX
OUTLOOK RATING
1..100
32
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
59
P/E GROWTH RATING
1..100
15
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
APYXEMBC
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
75%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 14 days ago
84%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 20 days ago
89%
Bearish Trend 6 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
73%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (APYX: $2.93 vs. EMBC: $6.43)
Brand notoriety: APYX and EMBC are both not notable
APYX represents the Medical/Nursing Services, while EMBC is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: APYX: 43% vs. EMBC: 85%
Market capitalization -- APYX: $123.42M vs. EMBC: $350.72M
APYX [@Medical/Nursing Services] is valued at $123.42M. EMBC’s [@Pharmaceuticals: Other] market capitalization is $350.72M. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $190.22B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $159.96B. The average market capitalization across the [@Medical/Nursing Services] industry is $6.17B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APYX’s FA Score shows that 2 FA rating(s) are green while EMBC’s FA Score has 2 green FA rating(s).

  • APYX’s FA Score: 2 green, 3 red.
  • EMBC’s FA Score: 2 green, 3 red.
According to our system of comparison, EMBC is a better buy in the long-term than APYX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APYX’s TA Score shows that 5 TA indicator(s) are bullish while EMBC’s TA Score has 3 bullish TA indicator(s).

  • APYX’s TA Score: 5 bullish, 5 bearish.
  • EMBC’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, APYX is a better buy in the short-term than EMBC.

Price Growth

APYX (@Medical/Nursing Services) experienced а +12.69% price change this week, while EMBC (@Pharmaceuticals: Other) price change was +5.76% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.96%. For the same industry, the average monthly price growth was +6.35%, and the average quarterly price growth was +22.73%.

Reported Earning Dates

APYX is expected to report earnings on Mar 18, 2027.

EMBC is expected to report earnings on Nov 24, 2026.

Industries' Descriptions

@Medical/Nursing Services (-2.89% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

@Pharmaceuticals: Other (+1.96% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
Interact to see
Advertisement

APYX and

Correlation & Price change

A.I.dvisor tells us that APYX and SGHT have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APYX and SGHT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APYX
1D Price
Change %
APYX100%
+2.39%
SGHT - APYX
28%
Poorly correlated
+1.58%
ITOC - APYX
26%
Poorly correlated
+8.46%
CLPT - APYX
25%
Poorly correlated
+4.56%
EMBC - APYX
25%
Poorly correlated
+1.56%
A - APYX
25%
Poorly correlated
-0.52%
More

EMBC and

Correlation & Price change

A.I.dvisor indicates that over the last year, EMBC has been loosely correlated with WAT. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if EMBC jumps, then WAT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EMBC
1D Price
Change %
EMBC100%
+1.56%
WAT - EMBC
37%
Loosely correlated
-0.97%
MTD - EMBC
37%
Loosely correlated
-0.14%
AVTR - EMBC
37%
Loosely correlated
+1.03%
RVTY - EMBC
36%
Loosely correlated
-0.53%
RGEN - EMBC
35%
Loosely correlated
-0.78%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TPFG23.910.63
+2.69%
Timothy Plan Free Cash Flow Growth ETF (TPFG)
SOUX3.210.08
+2.42%
Defiance Daily Target 2X Long SOUN ETF (SOUX)
COWG38.680.80
+2.10%
Pacer US Large Cap Cash Cows Growth Leaders ETF (COWG)
JMSI49.08-0.01
-0.02%
JPMorgan Sustainable Municipal Income ETF (JMSI)
PRSD24.65-0.01
-0.04%
State Street Short Duration IG Public & Private Credit ETF (PRSD)